30.39

3.65% 1.07

Pre-market: 30.39

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $30.39, with a volume of 961.16K. It is up +3.65% in the last 24 hours and up +0.07% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Previous Close:

$29.32

Open:

$29.45

24h Volume:

961.16K

Relative Volume:

0.69

Market Cap:

$2.90B

Revenue:

$70.79M

Net Income/Loss:

$-286.89M

P/E Ratio:

-8.6003

EPS:

-3.5336

Net Cash Flow:

$-326.34M

1W Performance:

+5.01%

1M Performance:

+0.07%

6M Performance:

+63.04%

1Y Performance:

+99.61%

1-Day Range:

$28.68

$30.69

1-Week Range:

$26.31

$30.69

52-Week Range:

$9.90

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

143

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	30.39	2.80B	70.79M	-286.89M	-326.34M	-3.5336
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

07:32 AM

Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat

07:32 AM

Mar 04, 2026

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa

Mar 04, 2026

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia

Mar 04, 2026

[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan

Mar 04, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com

Mar 04, 2026